Finish the Space Station, Head for Mars

There has never been an international civil engineering fiasco quite like the International Space Station (ISS). Its estimated total cost of $95 billion is almost 10 times what it would take to build the Panama Canal today, yet its end is nowhere in sight. The ISS was scheduled to be completed by 2000, but its projected completion has slipped to 2006 and may slip further. NASA friends and foes alike are asking: What will it take to finish the project? The scientists who can make the best use of

Written byRichard Wassersug
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The scientists who can make the best use of the ISS are biologists like myself—a space biologist with experiments to fly on the completed ISS—who are interested in the long-term effects of microgravity on living organisms. For us the ISS as originally planned was going to be—and could still be—a stellar laboratory for studying the growth and development of organisms in space through several generations. The sort of work that we do is fundamental to determining how dangerous extended space flight is for living organisms and how to mitigate the risks.

In the original ISS plans is a particularly elegant but admittedly expensive piece of hardware for biological research: a large centrifuge that would rotate at a speed sufficient to reproduce the 1-g gravitational force of Earth. That centrifuge is key to high-quality space biology simply because it would allow for a 1-g control on all flight experiments. Without it ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies